Moderna, Inc. Equity Securities, FV-NI, Realized Gain (Loss)
Moderna, Inc. (MRNA) reported Equity Securities, FV-NI, Realized Gain (Loss) of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiRealizedGainLoss · last filed 2026-07-31
- Moderna, Inc. equity securities, fv-ni, realized gain (loss) for the quarter ending 2026-06-30 was $0.00.
- Moderna, Inc. equity securities, fv-ni, realized gain (loss) for the quarter ending 2026-03-31 was -$2.00M.
- Moderna, Inc. equity securities, fv-ni, realized gain (loss) for the quarter ending 2025-12-31 was -$3.00M.
- Moderna, Inc. equity securities, fv-ni, realized gain (loss) for the quarter ending 2025-09-30 was $3.00M.
- Moderna, Inc. equity securities, fv-ni, realized gain (loss) for fiscal 2025 was -$8.00M.
- Moderna, Inc. equity securities, fv-ni, realized gain (loss) for fiscal 2024 was -$52.00M.
- Moderna, Inc. equity securities, fv-ni, realized gain (loss) for fiscal 2023 was -$35.00M.
| Period end | Equity Securities, FV-NI, Realized Gain (Loss) 3 month | Equity Securities, FV-NI, Realized Gain (Loss) 3 month as first filed | Equity Securities, FV-NI, Realized Gain (Loss) 6 month | Equity Securities, FV-NI, Realized Gain (Loss) 9 month | Equity Securities, FV-NI, Realized Gain (Loss) 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-07-31 | -$2.00M 10-Q · filed 2026-07-31 | -$5.00M derived: sum of 3 quarters · filed 2026-07-31 | -$2.00M derived: sum of 4 quarters · filed 2026-07-31 | |
| 2026-03-31 | -$2.00M 10-Q · filed 2026-05-01 | -$5.00M derived: sum of 2 quarters · filed 2026-05-01 | -$2.00M derived: sum of 3 quarters · filed 2026-05-01 | -$10.00M derived: sum of 4 quarters · filed 2026-07-31 | |
| 2025-12-31 | -$3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $0.00 derived: sum of 2 quarters · filed 2026-02-20 | -$8.00M derived: sum of 3 quarters · filed 2026-07-31 | -$8.00M 10-K · filed 2026-02-20 | |
| 2025-09-30 | $3.00M 10-Q · filed 2025-11-06 | -$5.00M derived: sum of 2 quarters · filed 2026-07-31 | -$5.00M 10-Q · filed 2025-11-06 | -$22.00M derived: sum of 4 quarters · filed 2026-07-31 | |
| 2025-06-30 | -$8.00M 10-Q · filed 2026-07-31 | $0.00 10-Q · filed 2025-08-01 | -$8.00M 10-Q · filed 2026-07-31 | -$25.00M derived: sum of 3 quarters · filed 2026-07-31 | -$33.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | -$8.00M 10-Q · filed 2026-05-01 | -$17.00M derived: sum of 2 quarters · filed 2026-05-01 | -$25.00M derived: sum of 3 quarters · filed 2026-05-01 | -$47.00M derived: sum of 4 quarters · filed 2026-05-01 | |
| 2024-12-31 | -$9.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$17.00M derived: sum of 2 quarters · filed 2026-02-20 | -$39.00M derived: sum of 3 quarters · filed 2026-02-20 | -$52.00M 10-K · filed 2026-02-20 | |
| 2024-09-30 | -$8.00M 10-Q · filed 2025-11-06 | -$30.00M derived: sum of 2 quarters · filed 2025-11-06 | -$43.00M 10-Q · filed 2025-11-06 | -$62.00M derived: sum of 4 quarters · filed 2026-02-20 | |
| 2024-06-30 | -$22.00M 10-Q · filed 2025-08-01 | -$35.00M 10-Q · filed 2025-08-01 | -$54.00M derived: sum of 3 quarters · filed 2026-02-20 | -$87.00M derived: sum of 4 quarters · filed 2026-02-20 | |
| 2024-03-31 | -$13.00M 10-Q · filed 2025-05-01 | -$32.00M derived: sum of 2 quarters · filed 2026-02-20 | -$65.00M derived: sum of 3 quarters · filed 2026-02-20 | -$29.00M derived: sum of 4 quarters · filed 2026-02-20 | |
| 2023-12-31 | -$19.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$52.00M derived: sum of 2 quarters · filed 2026-02-20 | -$16.00M derived: sum of 3 quarters · filed 2026-02-20 | -$35.00M 10-K · filed 2026-02-20 | |
| 2023-09-30 | -$33.00M 10-Q · filed 2024-11-07 | $3.00M derived: sum of 2 quarters · filed 2024-11-07 | -$16.00M 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $36.00M 10-Q · filed 2024-08-01 | $17.00M 10-Q · filed 2024-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |